Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

letetresgene autoleucel

Human autologous T lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T lymphocytes GSK3377794
autologous T-cells expressing enhanced TCRs specific for NY-ESO-1/LAGE-1a GSK3377794
genetically engineered NY-ESO-1 specific [c259] T cells GSK3377794
genetically engineered NY-ESO-1/LAGE-1 specific (c259) T cells GSK3377794
NY-ESO-1c259 T cells GSK3377794
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search